Hiroshi Wada1, Hidetoshi Eguchi2, Hiroaki Nagano1, Shoji Kubo3, Takuya Nakai4, Masaki Kaibori5, Michihiro Hayashi6, Shigekazu Takemura3, Shogo Tanaka3, Yasuyuki Nakata4, Kosuke Matsui5, Morihiko Ishizaki5, Fumitoshi Hirokawa6, Koji Komeda6, Kazuhisa Uchiyama6, Masanori Kon5, Yuichiro Doki1, Masaki Mori1. 1. Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan. 2. Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan. heguchi@gesurg.med.osaka-u.ac.jp. 3. Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Osaka, 545-8585, Japan. 4. Department of Surgery, Kinki University School of Medicine, Sayama, Osaka, 589-8511, Japan. 5. Department of Surgery, Hirakata Hospital, Kansai Medical University, Hirakata, Osaka, 573-1191, Japan. 6. Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Osaka, 569-8686, Japan.
Abstract
PURPOSE: The influence of allogenic blood transfusion on the postoperative outcomes of hepatocellular carcinoma (HCC) surgery remains controversial. This study aims to clarify the clinical impacts of perioperative allogenic blood transfusion on liver resection outcome in HCC patients. METHODS: We analyzed data collected over 5 years for 642 patients who underwent hepatectomy for HCC at one of the five university hospitals. We investigated the impact of allogenic blood transfusion on postoperative outcome after surgery in all patients and in 74 matched pairs, using a propensity score. RESULTS: Of the 642 patients, 198 (30.8%) received perioperative allogenic blood transfusion (AT group) and 444 (69.2%) did not (non-AT group). Overall survival was lower in the AT group than in the non-AT group in univariate (P < 0.001) and multivariate analyses (risk ratio 1.521, P = 0.011). After matching the different distributions using propensity scores, perioperative blood transfusion was found to be a poor prognostic factor for HCC patients. CONCLUSIONS: In this multi-center study, perioperative blood transfusion was an independent factor for poor prognosis after curative surgery for primary HCC in the patient group and in pairs matched by propensity scores.
PURPOSE: The influence of allogenic blood transfusion on the postoperative outcomes of hepatocellular carcinoma (HCC) surgery remains controversial. This study aims to clarify the clinical impacts of perioperative allogenic blood transfusion on liver resection outcome in HCC patients. METHODS: We analyzed data collected over 5 years for 642 patients who underwent hepatectomy for HCC at one of the five university hospitals. We investigated the impact of allogenic blood transfusion on postoperative outcome after surgery in all patients and in 74 matched pairs, using a propensity score. RESULTS: Of the 642 patients, 198 (30.8%) received perioperative allogenic blood transfusion (AT group) and 444 (69.2%) did not (non-AT group). Overall survival was lower in the AT group than in the non-AT group in univariate (P < 0.001) and multivariate analyses (risk ratio 1.521, P = 0.011). After matching the different distributions using propensity scores, perioperative blood transfusion was found to be a poor prognostic factor for HCC patients. CONCLUSIONS: In this multi-center study, perioperative blood transfusion was an independent factor for poor prognosis after curative surgery for primary HCC in the patient group and in pairs matched by propensity scores.
Authors: L S Jensen; A J Andersen; P M Christiansen; P Hokland; C O Juhl; G Madsen; J Mortensen; C Møller-Nielsen; F Hanberg-Sørensen; M Hokland Journal: Br J Surg Date: 1992-06 Impact factor: 6.939
Authors: J Yamamoto; T Kosuge; T Takayama; K Shimada; S Yamasaki; H Ozaki; N Yamaguchi; S Mizuno; M Makuuchi Journal: Surgery Date: 1994-03 Impact factor: 3.982